Healthtech Investors & VC Firms in Germany

144 firms in this list, with a median first check of $545K. 30 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
ON Onsight Ventures JGKGAWCH14 people	88🔒	Innsbruck	AT	Pre-Seed–Series A	$216K – $2.2M	+ Add to CRM
FO Forbion DHMBWJCI16 people	88🔒	Naarden	NL	Pre-Seed–Late Stage	—	+ Add to CRM
VE Vesper Infrastructure Partners AMGRGRLF16 people	88🔒	London	GB	Growth–Late Stage	—	+ Add to CRM
VE Vesta Software Group RCDBTMTB5 people	88🔒	Wallingford	GB	Growth	—	+ Add to CRM
PU PUSH Ventures LSLPDAMF6 people	88🔒	Vienna	AT	Pre-Seed–Series A	—	+ Add to CRM
FO Founder One CLSAAŞAŞ6 people	88🔒	Istanbul	TR	Pre-Seed–Seed	$100K – $1.4M	+ Add to CRM
BI BioGeneration Ventures DCEVKGOS22 people	88🔒	Naarden	NL	Seed–Late Stage	—	+ Add to CRM
HE Heal Capital CLDMEWDC13 people · Leads rounds	88🔒	Berlin	DE	Pre-Seed–Late Stage	$1.1M – $5.5M	+ Add to CRM
GI Gimv AJLTMMPV11 people · Leads rounds	88🔒	The Hague	NL	Growth–Late Stage	$21M – $430M	+ Add to CRM
EX Exceptional Ventures MCPPMBSC15 people	88🔒	London	GB	Pre-Seed–Series A	—	+ Add to CRM
RO Rocket Internet SE OSDAGJSM9 people	88🔒	Berlin	DE	Seed–Late Stage	—	+ Add to CRM
DI Dimension Capital BLAGNLNN13 people	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
AE Aescap Life Sciences PKPDBJGH14 people	88🔒	Amsterdam	NL	Seed–Growth	—	+ Add to CRM
NI Nina Capital SAANBSJP11 people · Leads rounds	88🔒	Barcelona	ES	Pre-Seed–Series A	$220K – $1.6M	+ Add to CRM
TH Think.Health FKMRNB3 people	88🔒	Berlin	DE	Seed–Growth	$550K – $11M	+ Add to CRM
PR Privilège Ventures JRAMCPHK12 people	88🔒	Lugano	CH	Pre-Seed–Series A	—	+ Add to CRM
PA PAI Partners AAAAEAEA8 people	88🔒	Paris	FR	Growth–Late Stage	$108M – $324M	+ Add to CRM
GR GR Capital MFDLSKAL6 people · Follows rounds	88🔒	London	GB	Series B–Growth	$3.2M – $10.8M	+ Add to CRM
LB LBBW Venture Capital GmbH AVFMCLMN9 people	88🔒	Stuttgart	DE	Seed–Late Stage	$540K – $3.2M	+ Add to CRM
NO Novalis Biotech JVWVKMJB9 people	88🔒	Ghent	BE	Pre-Seed–Series A	—	+ Add to CRM
FR Fresenius Medical Care Ventures AWAWASBH8 people	88🔒	Bad Homburg	DE	Seed–Late Stage	—	+ Add to CRM
4I 4impact capital ANPWVSYV6 people · Leads rounds	88🔒	The Hague	NL	Seed–Series A	—	+ Add to CRM
EQ EquityPitcher Ventures ASHKSHMM12 people	88🔒	Zürich	CH	Seed–Late Stage	—	+ Add to CRM
RK RKKVC EKMBAK3 people · Leads rounds	88🔒	Nicosia	CY	Seed–Series A	$108K – $1.1M	+ Add to CRM

Onsight Ventures

InnsbruckPre-Seed–Series A$216K – $2.2M

JGKGAWCH14 people

Forbion

NaardenPre-Seed–Late Stage

DHMBWJCI16 people

Vesper Infrastructure Partners

LondonGrowth–Late Stage

AMGRGRLF16 people

Vesta Software Group

WallingfordGrowth

RCDBTMTB5 people

PUSH Ventures

ViennaPre-Seed–Series A

LSLPDAMF6 people

Founder One

IstanbulPre-Seed–Seed$100K – $1.4M

CLSAAŞAŞ6 people

BioGeneration Ventures

NaardenSeed–Late Stage

DCEVKGOS22 people

Heal Capital

BerlinPre-Seed–Late Stage$1.1M – $5.5M

CLDMEWDC13 people

Gimv

The HagueGrowth–Late Stage$21M – $430M

AJLTMMPV11 people

Exceptional Ventures

LondonPre-Seed–Series A

MCPPMBSC15 people

Rocket Internet SE

BerlinSeed–Late Stage

OSDAGJSM9 people

Dimension Capital

San FranciscoSeed–Late Stage

BLAGNLNN13 people

Aescap Life Sciences

AmsterdamSeed–Growth

PKPDBJGH14 people

Nina Capital

BarcelonaPre-Seed–Series A$220K – $1.6M

SAANBSJP11 people

Think.Health

BerlinSeed–Growth$550K – $11M

FKMRNB3 people

Privilège Ventures

LuganoPre-Seed–Series A

JRAMCPHK12 people

PAI Partners

ParisGrowth–Late Stage$108M – $324M

AAAAEAEA8 people

GR Capital

LondonSeries B–Growth$3.2M – $10.8M

MFDLSKAL6 people

LBBW Venture Capital GmbH

StuttgartSeed–Late Stage$540K – $3.2M

AVFMCLMN9 people

Novalis Biotech

GhentPre-Seed–Series A

JVWVKMJB9 people

Fresenius Medical Care Ventures

Bad HomburgSeed–Late Stage

AWAWASBH8 people

4impact capital

The HagueSeed–Series A

ANPWVSYV6 people

EquityPitcher Ventures

ZürichSeed–Late Stage

ASHKSHMM12 people

RKKVC

NicosiaSeed–Series A$108K – $1.1M

EKMBAK3 people

Data sourced from public filings and firms' own websites — see our methodology.